Volume 1, Issue 1 (2020)

1. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001; 2(4):293-299. 

2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 331(6024):1565-70. 

3. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002; 3(11):999-1005. 

4. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003; 21:807-839. 5. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-998. 

6. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22:329-360. 

7. Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE. T regulatory cells in cancer: Recent advances and therapeutic potential. Expert Opin Biol Ther. 2010;10(11):1573-1586. 

8. Chaudhary B, Elkord E. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines (Basel). 2016; 4(3):28. 

9. Ondondo B, Jones E, Godkin A, Gallimore A. Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells. Front Immunol. 2013; 4:197